MRKR
Marker Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.18
−4.84%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-12.7%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Nov 19, 2025 | Knobil Katharine · director | A-Award | 137,330 | $0.95 |
| Nov 19, 2025 | ELMS STEVE · director | A-Award | 84,411 | $0.95 |
| Nov 19, 2025 | ELMS STEVE · director | A-Award | 137,330 | $0.95 |
| Nov 19, 2025 | Eansor Norman David · director | A-Award | 84,411 | $0.95 |
| Nov 19, 2025 | Eansor Norman David · director | A-Award | 137,330 | $0.95 |
| Nov 19, 2025 | Knobil Katharine · director | A-Award | 84,411 | $0.95 |
| Nov 4, 2025 | Vera Juan · director, officer: Chief Executive Officer | A-Award | 250,000 | $0.99 |
| Nov 4, 2025 | Corzo Kathryn Penkus · director | A-Award | 147,611 | $0.99 |
| Feb 14, 2025 | Vera Juan · director, officer: President and CEO | A-Award | 50,000 | $1.59 |
| Feb 14, 2025 | Knobil Katharine · director | A-Award | 30,000 | $1.59 |
| Feb 14, 2025 | ELMS STEVE · director | A-Award | 30,000 | $1.59 |
| Feb 14, 2025 | Eansor Norman David · director | A-Award | 30,000 | $1.59 |
| Dec 26, 2024 | ELMS STEVE · director | Purchase | 11,085 | $3.20 |
| Dec 23, 2024 | New Enterprise Associates 16, L.P. · 10 percent owner | Purchase | 554,250 | $3.20 |
| Jun 8, 2023 | Eansor Norman David · director | Purchase | 14,285 | $18 |
| Jun 8, 2023 | ELMS STEVE · director | A-Award | 8,000 | $1.72 |
| Jun 8, 2023 | Wilson John Robert · director | A-Award | 8,000 | $1.72 |
| Jun 8, 2023 | Knobil Katharine · director | A-Award | 8,000 | $1.72 |
| Jun 8, 2023 | Eansor Norman David · director | A-Award | 8,000 | $1.72 |
| May 11, 2023 | Vera Juan · director, officer: President and CEO | A-Award | 100,000 | $1.42 |
| Mar 1, 2023 | Agopyan Nadia · officer: SVP, Regulatory Affairs | A-Award | 34,154 | $2.14 |
| Mar 1, 2023 | Hoang Tsvetelina P · officer: VP, Research and Development | A-Award | 33,159 | $2.14 |
| Mar 1, 2023 | Koneru Mythili · officer: Chief Medical Officer | A-Award | 51,918 | $2.14 |
| Mar 1, 2023 | Loiacono Michael · officer: Chief Accounting Officer | A-Award | 38,480 | $2.14 |
| Mar 1, 2023 | Vera Juan · director, officer: Chief Scientific Officer & COO | A-Award | 46,487 | $2.14 |
| Mar 1, 2023 | Szymanska Anna · officer: Vice President, Quality | A-Award | 29,947 | $2.14 |
| May 26, 2022 | Eansor Norman David · director: | A-Award | 80,000 | $0.00 |
| May 26, 2022 | ELMS STEVE · director: | A-Award | 80,000 | $0.00 |
| May 26, 2022 | Knobil Katharine · director: | A-Award | 80,000 | $0.00 |
| May 26, 2022 | Laskow-Pooley David · director: | A-Award | 80,000 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 12Increased 12Reduced 16Sold out 4
| Filer | Action | Shares | Filed |
|---|---|---|---|
| NEA MANAGEMENT COMPANY, LLC | Unchanged | 1,625,678 | May 15, 2026 |
| NEA Management Company, LLC | Unchanged | 1,625,678 | Aug 14, 2026 |
| Blue Owl Capital Holdings LP | Unchanged | 554,250 | Aug 11, 2026 |
| BLUE OWL CAPITAL HOLDINGS LP | Reduced | 554,250 | May 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 426,169 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 389,319 | May 15, 2026 |
| Aisling Capital Management LP | Unchanged | 325,370 | Aug 13, 2026 |
| AISLING CAPITAL MANAGEMENT LP | Unchanged | 325,370 | May 5, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 249,423 | Aug 13, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 175,294 | May 14, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 160,910 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Reduced | 139,816 | Aug 12, 2026 |
| OSAIC HOLDINGS, INC. | Increased | 112,649 | Aug 14, 2026 |
| ADVISOR GROUP HOLDINGS, INC. | Reduced | 93,121 | May 15, 2026 |
| VANGUARD FIDUCIARY TRUST CO | Unchanged | 87,269 | Aug 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Nov 19, 2025